title: Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia.
abstract: In mid-February 2008, a panel of 10 nationally recognized schizophrenia research experts was assembled in a Schizophrenia Summit to focus on controversies that exist in treating patients with schizophrenia. The current literature related to the diagnosis and etiopathology of schizophrenia was evaluated regarding the identification of a prodromal phase, brain changes, cognitive impairments, genetic factors, and use of neuroimaging in patients with schizophrenia. Further, consideration was given to evidence supporting the neuroprotective benefits of atypical antipsychotic medications, the benefits of treating patients during the prodromal period, the use of combination antipsychotic medications, the need to improve cognitive function, and the management of substance abuse. Summit faculty member opinion is compared with field survey results, and recommendations are made for future research.
authors.affiliation: Department of Psychiatry, University of Cincinnati College of Medicine, 260 Stetson St., Suite 3224, Cincinnati, OH 45267-0559, USA. NASRALHA@UCMAIL.UC.EDU
authors.forename: Henry A
authors.initials: HA
authors.lastname: Nasrallah
authors.forename: Matcheri S
authors.initials: MS
authors.lastname: Keshavan
authors.forename: Francine M
authors.initials: FM
authors.lastname: Benes
authors.forename: David L
authors.initials: DL
authors.lastname: Braff
authors.forename: Alan I
authors.initials: AI
authors.lastname: Green
authors.forename: Raquel E
authors.initials: RE
authors.lastname: Gur
authors.forename: John M
authors.initials: JM
authors.lastname: Kane
authors.forename: Diana O
authors.initials: DO
authors.lastname: Perkins
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Weiden
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Weinberger
authors.forename: Christoph U
authors.initials: CU
authors.lastname: Correll
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000473:pathology; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D015897:Comorbidity; D003952:Diagnostic Imaging; D004359:Drug Therapy, Combination; D042241:Early Diagnosis; D020022:Genetic Predisposition to Disease; D006801:Humans; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics; D012569:Schizotypal Personality Disorder / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000453:epidemiology
chemical_list: D014150:Antipsychotic Agents